Parameswaran Hari

2005–2025 年に発表

173
論文数
20,803
被引用数
79
h 指数
170
i10 指数

被引用数

Parameswaran Hari の年別被引用数1990 年: 被引用 1 件2003 年: 被引用 1 件2005 年: 被引用 1 件2006 年: 被引用 7 件2007 年: 被引用 12 件2008 年: 被引用 11 件2009 年: 被引用 18 件2010 年: 被引用 24 件2011 年: 被引用 33 件2012 年: 被引用 38 件2013 年: 被引用 90 件2014 年: 被引用 108 件2015 年: 被引用 105 件2016 年: 被引用 98 件2017 年: 被引用 115 件2018 年: 被引用 103 件2019 年: 被引用 521 件2020 年: 被引用 838 件2021 年: 被引用 1,079 件2022 年: 被引用 1,043 件2023 年: 被引用 848 件2024 年: 被引用 1,369 件2025 年: 被引用 569 件2026 年: 被引用 10 件1991〜2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,733 件、この内訳の 27.6%ドイツ: 引用元論文 657 件、この内訳の 6.6%中国: 引用元論文 641 件、この内訳の 6.5%イタリア: 引用元論文 571 件、この内訳の 5.8%イギリス: 引用元論文 523 件、この内訳の 5.3%フランス: 引用元論文 503 件、この内訳の 5.1%スペイン: 引用元論文 480 件、この内訳の 4.8%オランダ: 引用元論文 353 件、この内訳の 3.6%カナダ: 引用元論文 327 件、この内訳の 3.3%オーストラリア: 引用元論文 224 件、この内訳の 2.3%日本: 引用元論文 216 件、この内訳の 2.2%スイス: 引用元論文 211 件、この内訳の 2.1%
0%27.6%その他 24.8%

分野

  • Medicine86.9%
  • Biochemistry, Genetics and Molecular Biology8.9%
  • Immunology and Microbiology2.6%
  • Engineering0.2%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Neuroscience0.2%
  • その他1%

トピック

  • Multiple Myeloma Research and Treatments11.8%
  • CAR-T cell therapy research11.5%
  • Protein Degradation and Inhibitors5.8%
  • Hematopoietic Stem Cell Transplantation5%
  • Peptidase Inhibition and Analysis3.2%
  • Immune Cell Function and Interaction3.1%
  • その他59.6%

共著者

全論文

検索で開く
  1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Farah Hossain, Syed Rizvi, Frank Fan, Yi Lin, Thomas G. Martin, Sundar Jagannath - The Lancet 2021 被引用: 1,664

  2. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 633

  3. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 320

  4. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2019 被引用: 616

  5. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

    著者: , , , , , , , , , , , , , , , - Nature Medicine 2020 被引用: 459

  6. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen - The Lancet Oncology 2019 被引用: 796

  7. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , - The Lancet Haematology 2023 被引用: 150

  8. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

    著者: , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2020 被引用: 711

  9. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 被引用: 191

  10. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 255

  11. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 被引用: 268

  12. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed Elemary, Nizar J. Bahlis, Thierry Façon, Lionel Karlin, Vincent Ribrag, Michel Attal, Hartmut Goldschmidt, Monika Engelhardt, Katja Weisel, Andréas Mackensen, Arnon Nagler, Dina Ben Yehuda, Irit Avivi, Noam Benyamini, Hila Magen‐Nativ, Antonio Palumbo, Michèle Cavo, Kensei Tobinai, Shinsuke Iida, Takaai Chou, Kenshi Suzuki, Hiroshi Kosugi, Masafumi Taniwaki, Kazutaka Sunami, Morio Matsumoto, Kiyoshi Ando, Peter Ganly, Hilary Blacklock, David Simpson, Anupkumar George, Fredrik Schjesvold, Bjørn Tore Gjertsen, Juan José Lahuerta, Joan Bladé, Albert Oriol Rocafiguera, María‐Victoria Mateos, Paula Rodríguez‐Otero, Sarah M. Larson, Djordje Atanackovic, Srinivas Devarakonda, Jacob D. Bitran, Jeffrey A. Zonder, Neil Morganstein, Mohammad Hay, Asher Chanan‐Khan, Gene Saylors, Ebenezer A. Kio, Ira Oliff, Dean Kirkel, Mikhail Shtivelband, Carrie Yuen, Andrew J. Yee, Jatin J. Shah, Myo Htut, Shahzad Raza, Saurabh Chhabra, Patrick J. Stiff, Parameswaran Hari, Bruce Bank, Ehsan Malek, Cristina Gasparetto, Ycaoub Faroun, Daniel W. Sherbenou, William Kreisle, Seema Singhal, Jacalyn Rosenblatt, Saad Z. Usmani, Wes Lee, Hana Safah, Jose Lutzky ほか 21 名 - The Lancet Haematology 2019 被引用: 253

  13. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth - The Lancet Haematology 2019 被引用: 281

  14. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 被引用: 1,143

  15. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study

    著者: , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 被引用: 110

  16. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma

    著者: , , , , , , - Blood Advances 2021 被引用: 60

  17. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 被引用: 354

  18. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 251

  19. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

    著者: , , , - Frontiers in Oncology 2019 被引用: 173

  20. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva - Leukemia 2020 被引用: 119

  21. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center

    著者: , , , , , , , - Cytotherapy 2017 被引用: 119

  22. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 259

  23. A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2020 被引用: 112

  24. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

    著者: , , , , , , - JAMA Oncology 2022 被引用: 39